GALECTIN 1 rescues microvascular alterations in alzheimer’s disease in in vivo and in vitro models involving endoplasmic reticulum stress pathways.

J PRESA, C POMILIO, S GORI, E MATZKIN, A ALAIMO, M SOIZA-RELLY, O PEREZ, R. RAMHORST, J BEAUQUIS, G RABINOVICH, F SARAVIA

San LUis

Congreso; Reunión Anual de la Sociedad Argentina de inmunología (SAI); 2023

Sociedad Argentina de Investigacion Clinica SAIC

GALECTIN 1 RESCUES MICROVASCULAR ALTERATIONS IN ALZHEIMER’S DISEASE IN IN VIVOAND IN VITRO MODELS INVOLVING ENDOPLASMIC RETICULUM STRESS PATHWAYSJessica Presa1, Carlos Pomilio1, Soledad Gori3, Eugenia Matzkin2, Agustina Alaimo3, Mariano Soiza-Relly4, Oscar Perez3,Rossana Ramhorst3, Juan Beauquis1, Gabriel Rabinovich1, Flavia Saravia11 Ibyme Conicet & Dpto Quimica Biológica FCEN UBA. 2 Ibyme Conicet. 3 Iquibicen Conicet & Dpto Qca Biologica FCEN UBA. 4Ifibyne UBA-ConicetAs a multifactorial pathology, Alzheimer’s disease (AD)exhibits marked vascular alterations that correlate withdisease progression. The immense impact of AD requiresnew and effective therapeutics. Galectins, a family ofproteins that bind to outer membrane oligosaccharides,trigger various cell responses involving immune and vascular modulation. Galectin-1 (Gal1) may have beneficialeffects on neurological disorders. We treated PDAPPJ20(Tg) mice -an AD model- with Gal1(3 weekly i.p. injections of 100 ug/dose, 9 injections). Tg-Gal1 mice showeda 50% reduction in perivascular Aβ compared to vehicle-treated littermates (Tg-Veh) (p